Chat with us, powered by LiveChat

Mobile Technology and Online Tools to Improve Asthma Control in Adolescents


Project Info

Project Description

ID: 1R44HL127826-01
TERM: 06/15 – 05/17

Asthma is the most common chronic illness affecting youth, with prevalence and morbidity being significant among adolescents. School-based and web-based asthma interventions have been shown to be effective with younger children. Yet, few interventions have been developed and tested with high school students, with only one currently deployed online. The efficacy of Asthma Self-Management for Adolescents (ASMA), an in-person evidence-based high school based intervention, has been established; we have also successfully commercialized technology products for youth that are built on 3C’s dynamic e-learning platform (DELP).

Objective: This Direct to Phase II SBIR project fully developed and preliminarily validated ASMA 2.0, an empirically-based dynamic e-health intervention to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control. We applied our demonstrated DELP platform to deploy this demonstrated asthma intervention. Building on ASMA’s success, ASMA 2.0 is grounded in social cognitive theory, motivational interviewing, and best practices for user interface design to create a product that can be disseminated to a broad audience of users. We accomplished three specific aims: (1) fully developed ASMA 2.0, including eight modules with core instructional topics, tailored sessions, and embedded interactive activities; (2) conducted a two group randomized pilot trial with 70, 9th – 12th graders with uncontrolled asthma from two NYC public high schools in order to assess the preliminary intervention effects of ASMA 2.0, and to evaluate the feasibility and acceptability of ASMA 2.0; and (3) finalized and prepared ASMA 2.0 for commercialization based on feedback from adolescents who participated in the pilot test of ASMA 2.0 and stakeholders who treat and/or educate adolescents with asthma or who are likely payers. We also evaluated the reach, acceptability, feasibility, and sustainability of the ASMA 2.0 product.